Table 2.
STI tests per LPHD, FSW visit, and positive STI tests
| Tests | Number of LPHD offering test (%) | Number of performed tests | Median number tests per LPHDa | Median proportion of tests per FSW visit in % (IQR)a | Number of FSW visits with positive test | Proportion of positive tests in % (IQR)a |
|---|---|---|---|---|---|---|
| HIV | 28 (100) | 3882 | 86.5 | 66.0 (47.9–86.8) | 8 | 0.2 (0.0–0.4) |
| Chlamydia trachomatis | 27 (96) | 5353 | 94.5 | 65.4 (50.7–83.6) | 366 | 6.8 (2.5–10.4) |
| Neisseria gonorrhoea | 26 (93) | 6005 | 143.5 | 77.1 (60.7–88.0) | 195 | 3.2 (0.0–5.3) |
| Syphilis | 27 (96) | 4474 | 135.0 | 61.6 (48.6–78.6) | 50 | 1.1 (0.0–1.3) |
| Trichomonas vaginalis | 18 (64) | 3200 | 67.0 | 45.2 (14.2–71.6) | 97 | 3.0 (0.0–15.4) |
IQR interquartile range
aincludes only those LPHD offering the respective test